Sign inJoin waitlistJoin the waitlist

Marcela Maus

Physician · Massachusetts General Hospital

Credentials: · · · ·

History

Massachusetts General Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2009–2012
Hospital of the University of Pennsylvania
2006–2008
Howard Hughes Medical Institute
2005–2006
Perelman School of Medicine at the University of Pennsylvania
Perelman School of Medicine at the University of Pennsylvania
2001–2005
Massachusetts Institute of Technology (MIT
1997–2001

Research

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Review · Biology of Blood and Marrow Transplantation · 2019 · 3,048 citations
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Science Translational Medicine · 2017 · Last of 21 authors · Corresponding · 1,567 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 1,419 citations

MF
Matthew Frigault
52 papers · 4 as a fellow
Mark Leick
49 papers
Carl June
36 papers
Bryan Choi
27 papers · 15 as a resident
David Porter
11 papers
Jorg Dietrich
10 papers
Max Jan
10 papers · 5 as a fellow
NR
Noopur Raje
9 papers
Areej El-Jawahri
8 papers
Bob Carter
8 papers
Sarah Nikiforow
8 papers
Stephan Grupp
8 papers

Grants

Novel CAR T Cell Engineering Strategies for Effective Eradication of Solid and Liquid Tumors
National Cancer Institute · R01
Contact PI · $4M · Massachusetts General Hospital
2019–2030
Bioactivity of CAR T Cells Secreting T Cell Engager-Anitbodies in Humans with Glioblastoma
National Cancer Institute · R01
Contact PI · $3.1M · Massachusetts General Hospital
2024–2029
CAR T Cells Targeting Mesothelin and Secreting Bispecific Antibodies Targeting Fibroblasts in Pancreatic Cancer
National Cancer Institute · UH3
Contact PI · $4.5M · Massachusetts General Hospital
2025–2028
Understanding and Manipulating Programmed Cell Death (PCD) Pathways to Facilitate Lymphoid Tumor Killing by CAR T Cells
National Cancer Institute · R01
Contact PI · $3.5M · Massachusetts General Hospital
2021–2025